Oct. 9, 2017 – Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers and keloids with Superficial Radiation Therapy (SRT), announced today that an abstract was presented at the American Society for Dermatologic Surgery (ASDS) Annual Meeting, which took place on Oct. 5-8 in Chicago, illustrating the low recurrence rate of keloids post-keloidectomy with a biological effective dose 30 (BED 30) of SRT.
Recurrences of keloids are notorious in that approximately 71 percent of cases recur following a keloid excision alone. In comparison, the abstract reports a significantly lower keloid recurrence rate – less than 2 percent – when combining keloidectomy and excision site treatment with SRT (BED 30).
“This important abstract details the advantages of SRT for the treatment and prevention of keloids,” said Joe Sardano, President and CEO of Sensus Healthcare. “Due to how difficult they are to treat and their high rate of recurrence, Keloids can become a major affliction, significantly impacting a patients’ quality of life on a daily basis. The findings of this abstract highlight the fact that SRT is a safe and extremely effective supplement in treating existing keloid conditions and reducing the recurrence rate when combined with excision surgery.”
Authored by Dr. Brian Berman, M.D., Ph.D., and presented at ASDS by Dr. Mark Nestor, M.D., Ph.D., the abstract, entitled, “Low Rate of Keloid Recurrences Following Treatment of Keloidectomy Sites with a Biological Effective Dose 30 of Superficial Radiation,” will also be presented at the upcoming Fall Clinical Dermatology Conference on Oct. 12-15, 2017, at The Wynn in Las Vegas.